clinical trial · NCT06435442
PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers
JW Pharmaceutical·phase1·completed·n = 57
HealthyEpaminurad, NaproxenEpaminuradEpaminurad placebo
brief summary
A Phase 1 Study to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and Naproxen in Healthy Volunteers
started
Jun 3, 2024
primary completion
Dec 30, 2025
completion
Dec 30, 2025
last updated
Apr 16, 2026
detailed description
Part 1: to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and Naproxen in Healthy Koreans/ Part 2: to evaluate the safety, PK/PD of Epaminurad in Healthy Caucasians
official title
A Phase 1 Study to Evaluate the Safety and PK/PD Drug-drug Interaction Between Epaminurad and Naproxen or to Assess the Safety and Multiple-Dose PK/PD Characteristics of Epaminurad in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol